GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Inventories, Finished Goods

Y-Biologics (XKRX:338840) Inventories, Finished Goods : ₩0 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Inventories, Finished Goods?


Y-Biologics Inventories, Finished Goods Historical Data

The historical data trend for Y-Biologics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Inventories, Finished Goods Chart

Y-Biologics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial - - - - -

Y-Biologics Quarterly Data
Dec17 Dec18 Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Y-Biologics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Y-Biologics Business Description

Traded in Other Exchanges
N/A
Address
B715 Daedeok Biz Center, 17 Techno 4-ro, Yuseong-gu, Daejeon, KOR, 34013
Y-Biologics Inc is a company that has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of the development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics Headlines

No Headlines